In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Utility of feature tracking cardiac magnetic resonance in significant chronic aortic regurgitation

Session Poster session 2

Speaker Tatiana Mallely Matajira Chia

Event : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance: Valve Disease
  • Session type : Poster Session

Authors : TM Matajira Chia (Salamanca,ES), S Merchan Gomez (Salamanca,ES), J Urmeneta Ulloa (Salamanca,ES), L Alvarez Rodriguez (Salamanca,ES), M Gonzalez Ruiz (Salamanca,ES), A Martin Garcia (Salamanca,ES), E Diaz Pelaez (Salamanca,ES), M Barreiro Perez (Salamanca,ES), M Delgado Gallego (Salamanca,ES), M Bastos Hernandez (Salamanca,ES), PL Sanchez (Salamanca,ES)

TM Matajira Chia1 , S Merchan Gomez2 , J Urmeneta Ulloa1 , L Alvarez Rodriguez1 , M Gonzalez Ruiz1 , A Martin Garcia2 , E Diaz Pelaez2 , M Barreiro Perez3 , M Delgado Gallego2 , M Bastos Hernandez1 , PL Sanchez3 , 1Hospital Clínico Universitario, Cardiac Imaging Unit - Salamanca - Spain , 2Hospital Clínico Universitario, Cardiology Department.IBSAL-CIBER-CV - Salamanca - Spain , 3Hospital Clínico Universitario, Cardiology Unit -IBSAL-CIBER-CV - Salamanca - Spain ,

European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii345


Current guidelines recomend aortic valve surgery in severe regurgitation aortic (AR) in asymptomatic patients with preserved LVEF based on evidence of significant dilation of the left ventricle (LV), in some cases it is insufficient. Feature tracking (FT) cardiac magnetic resonance (CMR) can help us for an early detection and, it allows you to choose the best time of surgery.


Analyze added forecast value of FT in patients with AR. We also studied whether there were differences in terms of FT between the different etiologies of AR.

Retrospective observational study in a cohort of patients with severe AR (regurgitant fraction > 33 %) match with health subjets control group.

Group I; 72,3 % were in functional NYHA class I .Regarding the CRM data, there were significant differences in LVEF (lower in the AR group), LV volume and global myocardial mass (higher in AR). On the subjetc of FT, there were significant differences in radial (RS) and longitudinal strain (LS) (lower in the AR group), but not in the circumferential strain (CS). We analyzed each of the etiologies of the AR without finding significant differences.

In the group of patients with AR, 66.2% continued clinical follow-up, 30.8% underwent surgery.
There were no significant differences in the rate of surgeries in relation to RS, LS or CS(p 0.068, p 0.083, p 0.434, respectively), or in mortality in relation to RS, LS or CS (p 0.812, p 0.741, p 0.547).


Patients with AR have worse values of strain. This fact could allow to detect patients with myocardial damage and indicate surgery earlier. There are no differences in strain depending on AR etiology

Group I. AR n: 65 Group II.Control n: 66 P value
Age (Media +/- DS) 56,66 +/- 17,02 54,67 +/- 18,47 0,11
Male 49 (75%) 30 (59%) 0,36
LVEF (%) 56,32% +/- 1,19 65,58 +/- 0,85 0,00
LVEDV (ml) 130,34 +/- 4,8 75,33 +/- 2,39 0,00
Mass (gr) 226,54 +/- 20,53 160,33 +/- 19,36 0,009
Radial Strain -41,10 +/- 2,75 -51,73 +/-3,99 0,00
Longitudinal Strain -16,04 +/- 1,01 -16,67 +/- 3,26 0,00
Circumferencial strain -24,7 +/- 1,34 -27,15+/- 1,73 0,76
Demographic and FT characteristics

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are